Where initially DNA sequencing approaches tested individual cancer ‘hotspot’ loci (e.g. KRAS mutational status in colorectal cancer; EGFR mutational status in lung cancer), a more precise understanding of the biological basis of malignancy subsequently led to identification and deployment of specific ‘cancer gene panels’ as prognostic or treatment prediction tools. This evidence concerns the gene EGFR and cancer.